Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death

Journal of Ovarian Research

Volumn 8, Issue 1, 2015, Pages

  Kafara, Perrine ^a,b,c   Icard, Philippe ^a,b,c,d   Guillamin, Marilyne ^a,b,c   Schwartz, Laurent ^d   Lincet, Hubert ^e,f  

^a INSERM   (France)

^b NORMANDIE UNIVERSITÉ   (France)

^c Centre de Lutte Contre le Cancer F Baclesse   (France)

^d ÉCOLE POLYTECHNIQUE   (France)

^e CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

Bcl xL; Bim; Lipoic acid; Mcl 1; ovarian cancer; ROS

Indexed keywords

BIM PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; PROTEIN BCL XL; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; THIOCTIC ACID; APOPTOSIS REGULATORY PROTEIN; BCL2L1 PROTEIN, HUMAN; BCL2L11 PROTEIN, HUMAN; CISPLATIN; MCL1 PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN; PROTEIN BCL X;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE REGULATION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG RESPONSE; ENDOPLASMIC RETICULUM STRESS; FEMALE; HUMAN; HUMAN CELL; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; UPREGULATION; BIOSYNTHESIS; CARCINOMA; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; OVARIAN NEOPLASMS; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-LIKE PROTEIN 11; BCL-X PROTEIN; CARCINOMA; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; THIOCTIC ACID;

EID: 84935836048     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/s13048-015-0165-z     Document Type: Article

References (54)

1. Bilska A, Wlodek L. Lipoic acid - the drug of the future? Pharmacol Rep. 2005;57:570-7.
2. Packer L, Roy S, Sen CK. Alpha-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol. 1997;38:79-101. 79-101.
3. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 1790;2009:1149-60.
4. Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition. 2001;17:888-95.
5. de Oliveira AM, Rondo PH, Luzia LA, D'Abronzo FH, Illison VK. The effects of lipoic acid and alpha-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Diabetes Res Clin Pract. 2011;92:253-60.
6. Feuerecker B, Pirsig S, Seidl C, Aichler M, Feuchtinger A, Bruchelt G, et al. Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo. Cancer Biol Ther. 2012;13:1425-35.
7. Yoo TH, Lee JH, Chun HS, Chi SG. alpha-Lipoic acid prevents p53 degradation in colon cancer cells by blocking NF-kappaB induction of RPS6KA4. Anticancer Drugs. 2013;24:555-65.
8. Na MH, Seo EY, Kim WK. Effects of alpha-lipoic acid on cell proliferation and apoptosis in MDA-MB-231 human breast cells. Nutr Res Pract. 2009;3:265-71.
9. Michikoshi H, Nakamura T, Sakai K, Suzuki Y, Adachi E, Matsugo S, et al. alpha-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells. Cancer Lett. 2013;335:472-8.
10. Dozio E, Ruscica M, Passafaro L, Dogliotti G, Steffani L, Marthyn P, et al. The natural antioxidant alpha-lipoic acid induces p27(Kip1)-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells. Eur J Pharmacol. 2010;641:29-34.
11. Schwartz L, Guais A, Israel M, Junod B, Steyaert JM, Crespi E, et al. Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin. Invest New Drugs. 2013;31:256-64.
12. Vig-Varga E, Benson EA, Limbil TL, Allison BM, Goebl MG, Harrington MA. Alpha-lipoic acid modulates ovarian surface epithelial cell growth. Gynecol Oncol. 2006;103:45-52.
13. Cremer DR, Rabeler R, Roberts A, Lynch B. Safety evaluation of alpha-lipoic acid (ALA). Regul Toxicol Pharmacol. 2006;46:29-41.
14. Piotrowski P, Wierzbicka K, Smialek M. Neuronal death in the rat hippocampus in experimental diabetes and cerebral ischaemia treated with antioxidants. Folia Neuropathol. 2001;39:147-54.
15. Simbula G, Columbano A, Ledda-Columbano GM, Sanna L, Deidda M, Diana A, et al. Increased ROS generation and p53 activation in alpha-lipoic acid-induced apoptosis of hepatoma cells. Apoptosis. 2007;12:113-23.
16. Garcia-Saez AJ. The secrets of the Bcl-2 family. Cell Death Differ. 2012;19:1733-40.
17. Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol. 2000;2:156-62.
18. Zhang LN, Li JY, Xu W. A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia. Cancer Gene Ther. 2013;20:1-7.
19. Krishna S, Low IC, Pervaiz S. Regulation of mitochondrial metabolism: yet another facet in the biology of the oncoprotein Bcl-2. Biochem J. 2011;435:545-51.
20. Brotin E, Meryet-Figuière M, Simonin K, Duval RE, Villedieu M, Leroy-Dudal J, et al. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int J Cancer. 2010;126:885-95.
21. Villedieu M, Deslandes E, Duval M, Heron JF, Gauduchon P, Poulain L. Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment. Gynecol Oncol. 2006;101:507-19.
22. Lincet H, Kafara P, Giffard F, Abeilard-Lemoisson E, Duval M, Louis MH, et al. Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells. J Ovarian Res. 2013;6:72.
23. Varin E, Denoyelle C, Brotin E, Meryet-Figuiere M, Giffard F, Abeilard E, et al. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis. 2010;31:984-93.
24. Li G, Zhang S, Fang H, Yan B, Zhao Y, Feng L, et al. Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1. Biochem Biophys Res Commun. 2013;434:809-14.
25. Simonin K, N'diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, et al. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Apoptosis. 2013;18:492-508.
26. Zhang X, Varin E, Allouche S, Lu Y, Poulain L, Icard P. Effect of citrate on malignant pleural mesothelioma cells: a synergistic effect with cisplatin. Anticancer Res. 2009;29:1249-54.
27. Meynet O, Zunino B, Happo L, Pradelli LA, Chiche J, Jacquin MA, et al. Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice. Blood. 2013;122:2402-11.
28. WARBURG O. On the origin of cancer cells. Science. 1956;123:309-14.
29. Icard P, Lincet H. A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim Biophys Acta. 1826;2012:423-33.
30. Kruspig B, Nilchian A, Orrenius S, Zhivotovsky B, Gogvadze V. Citrate kills tumor cells through activation of apical caspases. Cell Mol Life Sci. 2012;69:4229-37.
31. Lepleux C, Abeilard-Lemoisson E, Duval M, Icard P, Lincet H. siPGK1 Sensitizes Chemoresistant Human Ovarian Cancer Cell Lines to Cisplatin. Anticancer Res. 2012;32:4277-86.
32. Zhang X, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P, et al. Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res. 2006;26:3561-6.
33. Poulain L, Lincet H, Duigou F, Deslandes E, Sichel F, Gauduchon P, et al. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Int J Cancer. 1998;78:454-63.
34. Jebahi A, Villedieu M, Petigny C, Brotin E, Louis MH, Abeilard E, et al. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-x-targeting strategies, provided that Bim expression is induced. Cancer Lett. 2014;10.
35. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519-29.
36. Yamasaki M, Iwase M, Kawano K, Sakakibara Y, Suiko M, Ikeda M, et al. alpha-Lipoic acid suppresses migration and invasion via downregulation of cell surface beta1-integrin expression in bladder cancer cells. J Clin Biochem Nutr. 2014;54:18-25.
37. Lee HS, Na MH, Kim WK. alpha-Lipoic acid reduces matrix metalloproteinase activity in MDA-MB-231 human breast cancer cells. Nutr Res. 2010;30:403-9.
38. McKee CS, Hill DS, Redfern CP, Armstrong JL, Lovat PE. Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma. Exp Dermatol. 2013;22:767-9.
39. Simonin K, Brotin E, Dufort S, Dutoit S, Goux D, N'diaye M, et al. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells. Mol Cancer Ther. 2009;8:3162-70.
40. Roulston A, Muller WJ, Shore GC. BIM, PUMA, and the achilles' heel of oncogene addiction. Sci Signal. 2013;6, e12.
41. Dai DL, Wang Y, Liu M, Martinka M, Li G. Bim expression is reduced in human cutaneous melanomas. J Invest Dermatol. 2008;128:403-7.
42. Cartron PF, Loussouarn D, Campone M, Martin SA, Vallette FM. Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme. Cell Death Dis. 2012;3:e421. doi:10.1038/cddis.2012.150.: e421.
43. Tomasina J, Malzert-Freon A, Giffard F, Brotin E, Louis MH, Abeilard E, et al. Sensitization of ovarian carcinoma cells to Bcl-xL-targeting strategies through indirect modulation of Mcl-1 activity by MR22388, a molecule of the tripentone family. J Ovarian Res. 2013;6:38-6.
44. Aggarwal BB, Sung B. NF-kappaB in cancer: a matter of life and death. Cancer Discov. 2011;1:469-71.
45. Casanelles E, Gozzelino R, Marques-Fernandez F, Iglesias-Guimarais V, Garcia-Belinchon M, Sanchez-Osuna M, et al. NF-kappaB activation fails to protect cells to TNFalpha-induced apoptosis in the absence of Bcl-xL, but not Mcl-1, Bcl-2 or Bcl-w. Biochim Biophys Acta. 1833;2013:1085-95.
46. Kleinkauf-Rocha J, Bobermin LD, Machado PM, Goncalves CA, Gottfried C, Quincozes-Santos A. Lipoic acid increases glutamate uptake, glutamine synthetase activity and glutathione content in C6 astrocyte cell line. Int J Dev Neurosci. 2013;31:165-70.
47. Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell. 2007;129:1337-49.
48. Min KJ, Seo BR, Bae YC, Yoo YH, Kwon TK. Antipsychotic agent thioridazine sensitizes renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated inhibition of Akt signaling and downregulation of Mcl-1 and c-FLIP(L). Cell Death Dis. 2014;5:e1063. doi:10.1038/cddis.2014.35.: e1063.
49. Yuzefovych LV, Ledoux SP, Wilson GL, Rachek LI. Mitochondrial DNA damage via augmented oxidative stress regulates endoplasmic reticulum stress and autophagy: crosstalk, links and signaling. PLoS One. 2013;8, e83349.
50. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012;48:158-67.
51. Verfaillie T, Rubio N, Garg AD, Bultynck G, Rizzuto R, Decuypere JP, et al. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ. 2012;19:1880-91.
52. Zhou Y, Shu F, Liang X, Chang H, Shi L, Peng X, et al. Ampelopsin Induces Cell Growth Inhibition and Apoptosis in Breast Cancer Cells through ROS Generation and Endoplasmic Reticulum Stress Pathway. PLoS One. 2014;9, e89021.
53. Verfaillie T, van VA, Garg AD, Dewaele M, Rubio N, Gupta S, et al. Pro-apoptotic signaling induced by photo-oxidative ER stress is amplified by Noxa, not Bim. Biochem Biophys Res Commun. 2013;438:500-6.
54. Schwartz L, Buhler L, Icard P, Lincet H, Steyaert JM. Metabolic treatment of cancer: intermediate results of a prospective case series. Anticancer Res. 2014;34:973-80.